Condition
Non-Hodgkin Lymphomas
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Completed2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05589896Phase 1Recruiting
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT00991211Phase 3CompletedPrimary
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
NCT01078922Phase 2TerminatedPrimary
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
NCT01085058Phase 2Completed
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy
Showing all 4 trials